Topical finasteride matches oral on hair count in head-to-head data while cutting serum DHT suppression roughly in half. Here is where each one earns its slot in a hair stack — and where it doesn't.
Topical finasteride is the compromise that actually works on paper. The 2022 phase III data and the 2021 systematic review both put 0.25% topical solution within striking distance of 1mg oral on hair count, with markedly less serum DHT suppression. That is the entire pitch: keep scalp DHT crushed, leave systemic DHT mostly alone, and dodge the sexual and neuro sides that push a meaningful minority of users off oral. The catch is that "mostly alone" is doing real work in that sentence, and the vehicle, concentration, and frequency change the answer.
The cleanest comparison is the Piraccini et al. phase III trial of 0.25% topical finasteride spray vs 1mg oral. Both arms produced statistically significant hair count improvements over placebo, and the topical arm was non-inferior on the primary endpoint. Critically, scalp DHT reduction was comparable between arms (~68-75%), while serum DHT suppression diverged sharply: roughly 70% with oral, roughly 30-40% with 0.25% topical at the doses studied.
The 2021 meta-analysis PMID 34634163 lands in the same place: "Topical finasteride significantly improves hair count compared to placebo and is well tolerated. Its effect is similar to that of oral finasteride."
What that buys, in practice:
What it does not buy: a guaranteed side-free experience. Some topical finasteride absolutely reaches systemic circulation, and a subset of users report the same sexual or cognitive complaints they get from oral. The dose-response is shifted, not eliminated.
The trial concentration is 0.25% applied at 100-200 microliters per dose, once daily. Compounded and research-grade preparations in the wild span a wider range:
| Concentration | Typical use case | Notes |
|---|---|---|
| 0.025-0.1% | Cautious users, side-sensitive subjects | Lower systemic load; may underperform on dense vertex loss |
| 0.25% | Trial-matched standard | Best evidence base |
| 0.5-1% | Aggressive hair-focused stacks | More systemic absorption; closer to oral side profile |
Vehicle matters as much as concentration. Hydroalcoholic and propylene-glycol bases penetrate efficiently; liposomal preparations are marketed as reducing systemic uptake but the data is thin. Combo formulas pairing finasteride with minoxidil in a single solution are popular for compliance reasons, though they lock the application cadence of both agents together.
A representative protocol from the looksmaxxing hair community:
Topical earns its slot for three distinct personas:
Oral still wins on cost, convenience, and the depth of the long-term efficacy record. A 1mg tablet split into quarters runs cents per day; a research-grade topical solution runs $30-60 per month. For users who tolerate oral cleanly — and that is the majority — there is no efficacy reason to switch.
"Topical finasteride, which is reportedly just as effective but acts more locally (rather than systemically). Unfortunately, it also costs more per month." — community discussion
For a hair-focused looksmaxxing stack running alongside AAS, the decision tree usually looks like this:
The honest answer on topical vs oral cannot come from how the scalp feels at week 4. The protocol needs the same evaluation rigor as any other hair intervention:
Topical 0.25% finasteride is not a marketing dodge — it is a real efficacy-matched alternative to 1mg oral with a meaningfully lower systemic DHT footprint. For users who tolerate oral, oral remains the default on cost and evidence depth. For users who don't, or who are stacking aggressively and want to keep systemic androgen activity intact, topical earns its slot. Either way, finasteride is one leg of the stool: minoxidil, microneedling, and a topical AR antagonist on cycle are what turn a defensive protocol into an offensive one.
Powered by BTST